Vitamin D in autoimmune bullous disease

Tukaj, Stefan

doi:10.18388/abp.2020_2905

Cited by 5 publications

(4 citation statements)

References 48 publications

(86 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The hormonally active, UVB-induced vitamin D metabolite, 1,25-dihydroxyvitamin D 3 (calcitriol), participates in regulation of immune responses through binding to the vitamin D receptor expressed in multiple cells of the immune system [ 8 ]. There are several lines of evidence indicating vitamin D involvement in AIBD.…”

Section: Discussionmentioning

confidence: 99%

“…Similar to what has been previously described in ANA-positive healthy individuals [ 6 , 7 ], we hypothesized that an abnormal status of immunomodulatory vitamin D could play a role in anti-BP180-NC16A reactivity in healthy people. In fact, hypovitaminosis D has been reported to be more common in AIBD patients than in the general population [ 8 , 9 ], but nothing is known about vitamin D and BP autoantibodies in healthy populations. In addition, we aimed to evaluate the cytokine profile of anti-BP180-NC16A IgG-reactive versus anti-BP180-NC16A IgG-negative healthy blood donors, considering that an altered cytokine expression is found in BP patients [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Bullous pemphigoid anti-BP180-NC16A autoantibody reactivity in healthy individuals is associated with marked hypovitaminosis D and Th2-like cytokine predominance

et al. 2022

Self Cite

View full text Add to dashboard Cite

Autoimmune bullous disease autoantibodies, particularly including bullous pemphigoid (BP)-related anti-BP180-NC16A IgG, have been reported in a small subset of healthy individuals, but information about associated factors is lacking. We hypothesized that an abnormal status of immunomodulatory vitamin D could play a role in anti-BP180-NC16A autoantibody reactivity in healthy persons. In addition, we aimed to evaluate the cytokine profile associated with these autoantibodies. Plasma samples from 34 anti-BP180-NC16A IgG-reactive and 85 anti-BP180-NC16A IgG-negative healthy blood donors were tested for levels of 25-hydroxyvitamin D [25(OH)D] and a wide range of cytokines (IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, IL-17A, IL-17F, IL-21, IL-22, IFN-γ, and TNF-α). We observed that anti-BP180-NC16A IgG-reactive healthy subjects had significantly lower plasma 25(OH)D levels and about a two-fold higher rate of vitamin D deficiency (< 20 ng/ml) compared to anti-BP180-NC16A IgG-negative healthy persons. In addition, anti-BP180-NC16A IgG-positive samples were characterized by significantly higher levels of IL-2, IL-5, IL-9, IL-10, and IL-13 which were, however, not significantly associated with the vitamin D levels. Our results indicate that healthy individuals with BP autoantibody reactivity share similarities with BP patients regarding the vitamin D status and cytokine profile (i.e., marked hypovitaminosis D and Th2 predominance), which may have pathophysiologic implications.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Bullous pemphigoid anti-BP180-NC16A autoantibody reactivity in healthy individuals is associated with marked hypovitaminosis D and Th2-like cytokine predominance

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Nevertheless, there is strong evidence indicating an elevated prevalence of VDD among older age subjects [ 27 , 28 ], persons with darker skin pigmentation [ 44 ], obesity, and metabolic syndrome [ 27 , 45 ]. High VDD was demonstrated in patients with metabolic bone disorders [ 46 ], autoimmune diseases [ 47 , 48 , 49 ], including rheumatic disorders [ 50 , 51 , 52 , 53 ], inflammatory bowel diseases [ 54 , 55 ], infectious diseases [ 56 , 57 ], endocrine system disorders (type I diabetes mellitus, thyroid diseases, etc.) [ 58 , 59 , 60 ], cardiovascular [ 61 , 62 , 63 ], nervous system disorders [ 64 , 65 , 66 ], kidney diseases [ 67 ], chronic obstructive pulmonary disease [ 68 ], and tumors [ 69 ].…”

Section: Consensus Recommendationsmentioning

confidence: 99%

Ukrainian Consensus on Diagnosis and Management of Vitamin D Deficiency in Adults

Grygorieva,

Tronko,

Kovalenko

et al. 2024

Nutrients

View full text Add to dashboard Cite

Vitamin D deficiency (VDD) is a global problem, however, there were no Ukrainian guidelines devoted to its screening, prevention, and treatment, which became the reason for the Consensus creation. This article aimed to present the Consensus of Ukrainian experts devoted to VDD management. Following the creation of the multidisciplinary Consensus group, consent on the formation process, drafting and fine-tuning of key recommendations, and two rounds of voting, 14 final recommendations were successfully voted upon. Despite a recent decrease in VDD prevalence in Ukraine, we recommend raising awareness regarding VDD’s importance and improving the strategies for its decline. We recommend screening the serum 25-hydroxyvitamin D (25(OH)D) level in risk groups while maintaining a target concentration of 75–125 nmol/L (30–50 ng/mL). We recommend prophylactic cholecalciferol supplementation (800–2000 IU/d for youthful healthy subjects, and 3000–5000 IU/d for subjects from the risk groups). For a VDD treatment, we recommend a short-term administration of increased doses of cholecalciferol (4000–10,000 IU/d) with 25(OH)D levels monitored after 4–12 weeks of treatment, followed by the use of maintenance doses. Additionally, we recommend assessing serum 25(OH)D levels before antiosteoporotic treatment and providing vitamin D and calcium supplementation throughout the full course of the antiosteoporotic therapy.

show abstract

“…Проте накопичено достатньо даних щодо збільшення частки ДВД в осіб старших вікових груп [1,32,35], осіб з надмірною масою тіла та метаболічним синдромом [1,32,58], темною пігментацією шкіри [59]. Крім того, продемонстровано збільшення ДВД у хворих з метаболічними захворюваннями кісткової тканини [60], осіб з інфекційною [61,62] та автоімунною патологією [63,64,65], зокрема запальними захворюваннями кишечника [66,67], ревматичною патологією [68][69][70][71] тощо, захворюваннями ендокринної системи, зокрема цукровим діабетом [72,73], гіпогонадизмом [74], патологією щитоподібної залози [75,76] тощо, захворюваннями серцево-судинної [77][78][79][80], нервової системи [81][82][83], нирок [84], онкологічними захворюваннями [85], тривалим прийомом лікарських засобів з негативним впливом на метаболізм вітаміну D [86,87], а також зв'язок зі збільшеним рівнем смертності з різних причин [88][89][90][91]. Тому визначення сироваткового рівня 25(OH)D у цієї категорії осіб може бути корисним для ефективної профілактики й лікування ДВД [15,22,…”

Section: скринінг дефіциту вітаміну D у дорослихunclassified

Diagnosis, prevention and treatment of vitamin D deficiency in adults: Ukrainian experts consensus statement

Grygorieva,

Tronko,

Kovalenko

et al. 2023

PJS

View full text Add to dashboard Cite

Background. Vitamin D deficiency (VDD) is widespread in the world; its proportion varies considerably in different populations and depends on many causes. Up to now, there were no National recommendations for the diagnosis, prevention, and treatment of VDD in adults in Ukraine. Their creation became the purpose of this work. Methodology. Consensus was created using the Delphi method, voting was conducted using the SurveyMonkey® platform. After approval of the composition of the Consensus Group, agreement on the order of formation and structure of the Consensus, creation and correction of the main statements, and two voting rounds, the main Consensus statements were formed and were successfully voted on. The 15 authors of the article are 15 experts who participated in the voting. The final 14 Consensus statements are presented in this article. Each statement is preceded by a justification based on high-quality evidence available in the current literature. Results. Despite the reduction of VDD in the Ukrainian population in recent years, experts have recommended increasing the awareness of the medical community and the Ukrainian population about the problem and ways to overcome it, with a screening of the total serum level of 25-hydroxyvitamin D (25(OH)D) in subjects from the groups of risk to achieve the target concentration of 30–50 ng/ml (75–125 nmol/l). To ensure it, we recommend the individual selection of a prophylactic dose of vitamin D (800–2000 IU/d for young healthy persons and 3000–5000 IU/d for patients with diseases and conditions that affect the metabolism of vitamin D). For the treatment of VDD, we recommend short-term intake of higher doses (4000–10,000 IU/d) of vitamin D with control of the 25(OH)D level after 4–12 weeks of treatment and subsequent use of maintenance doses. Also, we recommend the determination of serum 25(OH)D level before the initiation of antiosteoporotic therapy in patients with osteoporosis and its complications to prevent its ineffectiveness and increase the safety profile.

show abstract

Vitamin D in autoimmune bullous disease

Cited by 5 publications

References 48 publications

Bullous pemphigoid anti-BP180-NC16A autoantibody reactivity in healthy individuals is associated with marked hypovitaminosis D and Th2-like cytokine predominance

Bullous pemphigoid anti-BP180-NC16A autoantibody reactivity in healthy individuals is associated with marked hypovitaminosis D and Th2-like cytokine predominance

Ukrainian Consensus on Diagnosis and Management of Vitamin D Deficiency in Adults

Diagnosis, prevention and treatment of vitamin D deficiency in adults: Ukrainian experts consensus statement

Contact Info

Product

Resources

About